Donald Trump has made tariffs a key part of his second term. He believes they can help transform the country.
And a new tariff deal from the Trump administration has these industry leaders rejoicing.
President Trump just pulled off another masterstroke in the endless battle to put America First. While the globalist elites whine about “free trade,” Trump reminded the world that trade only works when it’s FAIR trade.
On Monday, the US and UK inked a deal that finally makes Britain stop ripping off American pharmaceutical giants and start paying what life-saving drugs are actually worth.
Here’s the bottom line: Britain just agreed to jack up the price it pays for brand-new American medicines by a whopping 25%. In exchange, America is lifting those Section 232 and future Section 301 tariffs on British drugs, ingredients, and medical tech.
United States Trade Representative Jamieson Greer stated: “The United States and the United Kingdom announce this negotiated outcome pricing for innovative pharmaceuticals, which will help drive investment and innovation in both countries.”
The real kicker is what happens to Britain’s infamous drug-rationing bureaucracy, NICE. For years this outfit has been blocking cutting-edge American treatments because they’re “too expensive” for the sacred NHS.
Trump just forced them to raise their stingy “quality-adjusted life year” threshold from £30,000 to £35,000. That’s thousands of pounds more per year of life saved – a direct win for American companies and the patients who actually get the drugs.
The British government tried to spin it like they’re just “keeping pace with the commercial and economic environment.”
And this isn’t some special favor just for US drugs. The new, higher threshold applies to ALL new medicines. That means British patients might finally get access to the revolutionary treatments their socialist healthcare system has been denying them for years – treatments American companies spent billions developing while Britain sat back and paid pennies.
Remember when NICE blocked Eli Lilly’s Alzheimer’s breakthrough and AstraZeneca’s breast-cancer k*ller? Those days are numbered. British patients have been suffering because their government wanted bargain-basement prices on drugs that cost a fortune to invent. Trump just ended that scam.
The ABPI industry group cheered that the deal will help patients get new medicines faster and make the UK more attractive for investment. Even GSK, a British giant, called it “good foundations” that “offer a real opportunity to secure the UK as an attractive global-leading environment for life sciences that rewards long-term innovation.”
Stock prices didn’t explode because, let’s face it, the UK is a tiny market – just 2% of AstraZeneca’s revenue. But the signal to investors is crystal clear: park your billions in America or places that respect American innovation, not penny-pinching bureaucracies.
This deal is pure Trump doctrine in action. For years he’s been hammering Europe to stop underpaying for American drugs while their own citizens get second-rate care.
Eurocrats hate it, but the math doesn’t lie: American patients pay the highest prices in the world so the rest of the planet can get US drugs cheap. Trump said no more – and Britain just became the first domino to fall.
No wonder major firms like AstraZeneca had paused or canceled UK investments. Why pour money into a country that claws back your profits through insane rebate schemes? Under this deal, those rebates drop to just 15% starting in 2026. That’s real money staying in the pockets of companies that actually cure diseases.
Bristol Myers Squibb’s CEO Chris Boerner couldn’t hide his excitement: “BMS anticipates being able to invest upwards of $500 million over the next 5 years.” And he added, “This agreement is a sign of progress and one that creates an environment conducive to our continued presence in the UK.”
The British Chambers of Commerce nailed it: pharmaceuticals are a fifth of everything the UK ships to America. Now they’ve locked in a sweetheart exemption that almost no one else on earth has.
Bottom line? Trump just proved again that when America stands tall and demands respect, even our closest allies fall in line.
British patients get better drugs, American companies get paid fairly, and the freeloaders finally contribute their fair share.
